Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

Anemia is a common complication in chronic kidney disease (CKD), and is associated with a
reduced quality of life, and an increased morbidity and mortality. The mechanisms involved …

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-
class new generation drugs for renal anemia. This extensive meta-analysis of randomized …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of oral
medicines being developed for the treatment of anemia in chronic kidney disease (CKD) …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Renal anaemia is a common and important complication in patients with chronic kidney
disease (CKD). The current standard‐of‐care treatment for renal anaemia in CKD patients …

Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a promising
new class of orally administered drugs currently in late-stage global clinical development for …

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

What is known and objective Previous studies based on small‐sample clinical data proved
that short‐term use of hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHD) inhibitors …